Cargando…

Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS

BACKGROUND: Recombinant adeno-associated virus (rAAV) is widely used in the neuroscience field to manipulate gene expression in the nervous system. However, a limitation to the use of rAAV vectors is the time and expense needed to produce them. To overcome this limitation, we evaluated whether unpur...

Descripción completa

Detalles Bibliográficos
Autores principales: Goodwin, Marshall S., Croft, Cara L., Futch, Hunter S., Ryu, Daniel, Ceballos-Diaz, Carolina, Liu, Xuefei, Paterno, Giavanna, Mejia, Catalina, Deng, Doris, Menezes, Kimberly, Londono, Laura, Arjona, Kefren, Parianos, Mary, Truong, Van, Rostonics, Eva, Hernandez, Amanda, Boye, Sanford L., Boye, Shannon E., Levites, Yona, Cruz, Pedro E., Golde, Todd E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053119/
https://www.ncbi.nlm.nih.gov/pubmed/32122372
http://dx.doi.org/10.1186/s13024-020-00361-z
_version_ 1783502978187001856
author Goodwin, Marshall S.
Croft, Cara L.
Futch, Hunter S.
Ryu, Daniel
Ceballos-Diaz, Carolina
Liu, Xuefei
Paterno, Giavanna
Mejia, Catalina
Deng, Doris
Menezes, Kimberly
Londono, Laura
Arjona, Kefren
Parianos, Mary
Truong, Van
Rostonics, Eva
Hernandez, Amanda
Boye, Sanford L.
Boye, Shannon E.
Levites, Yona
Cruz, Pedro E.
Golde, Todd E.
author_facet Goodwin, Marshall S.
Croft, Cara L.
Futch, Hunter S.
Ryu, Daniel
Ceballos-Diaz, Carolina
Liu, Xuefei
Paterno, Giavanna
Mejia, Catalina
Deng, Doris
Menezes, Kimberly
Londono, Laura
Arjona, Kefren
Parianos, Mary
Truong, Van
Rostonics, Eva
Hernandez, Amanda
Boye, Sanford L.
Boye, Shannon E.
Levites, Yona
Cruz, Pedro E.
Golde, Todd E.
author_sort Goodwin, Marshall S.
collection PubMed
description BACKGROUND: Recombinant adeno-associated virus (rAAV) is widely used in the neuroscience field to manipulate gene expression in the nervous system. However, a limitation to the use of rAAV vectors is the time and expense needed to produce them. To overcome this limitation, we evaluated whether unpurified rAAV vectors secreted into the media following scalable PEI transfection of HEK293T cells can be used in lieu of purified rAAV. METHODS: We packaged rAAV2-EGFP vectors in 30 different wild-type and mutant capsids and subsequently collected the media containing secreted rAAV. Genomic titers of each rAAV vector were assessed and the ability of each unpurified virus to transduce primary mixed neuroglial cultures (PNGCs), organotypic brain slice cultures (BSCs) and the mouse brain was evaluated. RESULTS: There was ~ 40-fold wide variance in the average genomic titers of the rAAV2-EGFP vector packaged in the 30 different capsids, ranging from a low ~ 4.7 × 10(10) vector genomes (vg)/mL for rAAV2/5-EGFP to a high of ~ 2.0 × 10(12) vg/mL for a capsid mutant of rAAV2/8-EGFP. In PNGC studies, we observed a wide range of transduction efficiency among the 30 capsids evaluated, with the rAAV2/6-EGFP vector demonstrating the highest overall transduction efficiency. In BSC studies, we observed robust transduction by wild-type capsid vectors rAAV2/6, 2/8 and 2/9, and by capsid mutants of rAAV2/1, 2/6, and 2/8. In the in vivo somatic brain transgenesis (SBT) studies, we found that intra-cerebroventricular injection of media containing unpurified rAAV2-EGFP vectors packaged with select mutant capsids resulted in abundant EGFP positive neurons and astrocytes in the hippocampus and forebrain of non-transgenic mice. We demonstrate that unpurified rAAV can express transgenes at equivalent levels to lysate-purified rAAV both in vitro and in vivo. We also show that unpurified rAAV is sufficient to drive tau pathology in BSC and neuroinflammation in vivo, recapitulating previous studies using purified rAAV. CONCLUSIONS: Unpurified rAAV vectors secreted into the media can efficiently transduce brain cells in vitro and in vivo, providing a cost-effective way to manipulate gene expression. The use of unpurified virus will greatly reduce costs of exploratory studies and further increase the utility of rAAV vectors for standard laboratory use.
format Online
Article
Text
id pubmed-7053119
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70531192020-03-10 Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS Goodwin, Marshall S. Croft, Cara L. Futch, Hunter S. Ryu, Daniel Ceballos-Diaz, Carolina Liu, Xuefei Paterno, Giavanna Mejia, Catalina Deng, Doris Menezes, Kimberly Londono, Laura Arjona, Kefren Parianos, Mary Truong, Van Rostonics, Eva Hernandez, Amanda Boye, Sanford L. Boye, Shannon E. Levites, Yona Cruz, Pedro E. Golde, Todd E. Mol Neurodegener Methodology BACKGROUND: Recombinant adeno-associated virus (rAAV) is widely used in the neuroscience field to manipulate gene expression in the nervous system. However, a limitation to the use of rAAV vectors is the time and expense needed to produce them. To overcome this limitation, we evaluated whether unpurified rAAV vectors secreted into the media following scalable PEI transfection of HEK293T cells can be used in lieu of purified rAAV. METHODS: We packaged rAAV2-EGFP vectors in 30 different wild-type and mutant capsids and subsequently collected the media containing secreted rAAV. Genomic titers of each rAAV vector were assessed and the ability of each unpurified virus to transduce primary mixed neuroglial cultures (PNGCs), organotypic brain slice cultures (BSCs) and the mouse brain was evaluated. RESULTS: There was ~ 40-fold wide variance in the average genomic titers of the rAAV2-EGFP vector packaged in the 30 different capsids, ranging from a low ~ 4.7 × 10(10) vector genomes (vg)/mL for rAAV2/5-EGFP to a high of ~ 2.0 × 10(12) vg/mL for a capsid mutant of rAAV2/8-EGFP. In PNGC studies, we observed a wide range of transduction efficiency among the 30 capsids evaluated, with the rAAV2/6-EGFP vector demonstrating the highest overall transduction efficiency. In BSC studies, we observed robust transduction by wild-type capsid vectors rAAV2/6, 2/8 and 2/9, and by capsid mutants of rAAV2/1, 2/6, and 2/8. In the in vivo somatic brain transgenesis (SBT) studies, we found that intra-cerebroventricular injection of media containing unpurified rAAV2-EGFP vectors packaged with select mutant capsids resulted in abundant EGFP positive neurons and astrocytes in the hippocampus and forebrain of non-transgenic mice. We demonstrate that unpurified rAAV can express transgenes at equivalent levels to lysate-purified rAAV both in vitro and in vivo. We also show that unpurified rAAV is sufficient to drive tau pathology in BSC and neuroinflammation in vivo, recapitulating previous studies using purified rAAV. CONCLUSIONS: Unpurified rAAV vectors secreted into the media can efficiently transduce brain cells in vitro and in vivo, providing a cost-effective way to manipulate gene expression. The use of unpurified virus will greatly reduce costs of exploratory studies and further increase the utility of rAAV vectors for standard laboratory use. BioMed Central 2020-03-02 /pmc/articles/PMC7053119/ /pubmed/32122372 http://dx.doi.org/10.1186/s13024-020-00361-z Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology
Goodwin, Marshall S.
Croft, Cara L.
Futch, Hunter S.
Ryu, Daniel
Ceballos-Diaz, Carolina
Liu, Xuefei
Paterno, Giavanna
Mejia, Catalina
Deng, Doris
Menezes, Kimberly
Londono, Laura
Arjona, Kefren
Parianos, Mary
Truong, Van
Rostonics, Eva
Hernandez, Amanda
Boye, Sanford L.
Boye, Shannon E.
Levites, Yona
Cruz, Pedro E.
Golde, Todd E.
Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
title Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
title_full Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
title_fullStr Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
title_full_unstemmed Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
title_short Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
title_sort utilizing minimally purified secreted raav for rapid and cost-effective manipulation of gene expression in the cns
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053119/
https://www.ncbi.nlm.nih.gov/pubmed/32122372
http://dx.doi.org/10.1186/s13024-020-00361-z
work_keys_str_mv AT goodwinmarshalls utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT croftcaral utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT futchhunters utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT ryudaniel utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT ceballosdiazcarolina utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT liuxuefei utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT paternogiavanna utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT mejiacatalina utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT dengdoris utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT menezeskimberly utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT londonolaura utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT arjonakefren utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT parianosmary utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT truongvan utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT rostonicseva utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT hernandezamanda utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT boyesanfordl utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT boyeshannone utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT levitesyona utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT cruzpedroe utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns
AT goldetodde utilizingminimallypurifiedsecretedraavforrapidandcosteffectivemanipulationofgeneexpressioninthecns